Facilitated by: Anthony Bossis Ph.D. 

Price: $50.00

During this event, we will present the findings from the 2016 landmark NYU School of Medicine clinical trial on psychedelic research aimed to relieve the psychological and existential suffering associated with a life-threatening illness or the end of life. The trial demonstrated the efficacy of a single psilocybin-generated mystical experience in helping individuals with cancer cultivate meaning, enhance existential and psycho-spiritual well-being and foster a greater acceptance of the dying process with less anxiety.  The scientific findings of reduction in depression, anxiety, hopelessness and demoralization will be presented along with implications for the future of palliative and hospice care and the study of thanatology and consciousness.  Psilocybin is the psychoactive compound found in specific species of mushrooms. Features of a mystical experience include unity, sacredness, transcendence, ineffability and an enhanced awareness of positive emotions including that of love. Mystical experiences offer a novel therapeutic approach to promote an openness to the mystery of death and to a deeper understanding for the study of meaning and spirituality.